A Phase IIIb/IV, Multicenter, Randomized, Open-Label, Two-Arm Study to Investigate the Efficacy, Safety, and Durability of Faricimab Administered up to Every 24 Weeks in Patients With Neovascular Age-Related Macular Degeneration
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs Faricimab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms CONSTANCE
- Sponsors Roche
- 03 Feb 2025 New trial record